Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of BRAF and MEK inhibition in KRAS mutant NSCLC cell line NCI-H358

ABSTRACT: Effect of BRAF and MEK inhibition in KRAS mutant NSCLC cell line NCI-H358

PROVIDER: PRJNA1131840 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data from CHST11 over-expression in A-549 or NCI-H358 cells

Project description:To examine the CHST11 controls transcriptome in NSCLC cells, we preformed the Affymetrix Human Genome U133 Plus 2.0 Array with empty vector or CHST11 expression vector in A-549 or NCI-H358 cells Then the transcriptome were compared with each other to see the CHST11-regulating gene in NSCLC cells

2022-08-31 | GSE131952 | GEO

ATAC-seq of NCI-H358 cells treated with KRAS G12C inhibitor sotorasib

Project description:ATAC-seq of sotorasib-resistant NCI-H358 cells treated with sotorasib

2025-07-15 | GSE266309 | GEO

Effect of BRAF and MEK inhibition in KRAS mutant NSCLC cell line NCI-H358

Project description:Paradoxical RAF activation by chemical RAF inhibitors (RAFi) is a well-understood ‘on-target’ biological and clinical phenomenon. In this experiment, we profile the time-dependent gene expression changes that are specific to dabrafenib, selumetinib and the combination of dabrafenib plus selumetinib.

2025-08-22 | GSE271504 | GEO

Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer

Project description:To determine the difference of gene expression profile in epithelial and mesenchymal KRAS mutant lung cancers, epithelial NCI-H358 cells were treated with TGFβ1 (4 ng/mL) or PBS for 14 days in order to induce epithelial to mesenchymal transition (EMT). Gene expression was determined in NCI-H358 cells before and after EMT induction. In addition, in order to investigate the effect of a MEK inhibitor trametinib on gene expression, mesenchymal NCI-H1792 cells were treated with 50 nM trametinib for 48 hours. Gene expression of H1792 cells for pre- and post-trametinib treatement was determined.

2017-03-15 | GSE79235 | GEO

A375 BRAF/MEK/Dual exome seq

Project description:This study contains 4 exomes of A375, parental, BRAF resistant population, MEK resistant population and a BRAF/MEK resistant population

| PRJEB34013 | ENA

Transcriptomic profile of melanoma clinical samples treated with BRAF and MEK- inhibitors

Project description:To analyse the RNA expression differences between melanoma tumour samples treated with BRAF and MEK-inhibitors at different time points

2024-05-03 | GSE165337 | GEO

Transcriptional profiles of melanoma metastases from patients responsive or resistant to BRAF/MEK inhibitor

Project description:Transcriptional profiles of formalin-fixed-paraffin-embedded melanoma metastases including pre-treatment (PRE) and post-treatment (POST) specimens from 50 patients treated with BRAF inhibitors or with BRAF and MEK inhibitors

2022-04-12 | GSE196434 | GEO

Expression profiling of V600E BRAF and RTK-activated cells upon MEK inhibition

2009-02-11 | GSE10086 | GEO

Transcription profiling of human panel of V600E BRAF and RTK-activated tumor cells and xenografts upon MEK inhibition

Project description:This study used microarray expression analysis to identify global changes in transcript alteration in response to MEK inhibition. Genes under ERK control were identified in a panel of V600E BRAF and RTK-activated tumor cells and xenografts, using short-term inhibition of ERK activity using the MEK inhibitor PD0325901 (Pfizer). Experiment Overall Design: Cell lines growing in culture (n=12) and murine xenografts (n=2) were treated with the MEK inhibitor PD0325901 or vehicle alone as control. Paired analysis of MEK inhibited to control samples was performed for two groups of tumor cells, V600E BRAF and RTK. Time course analysis was performed on one representative cell line in order to first determine the optimal time point to detect changes in all cell lines.

2009-02-20 | E-GEOD-10086 | biostudies-arrayexpress

protein levels in BRAF/MEK inhibitor resistance melanoma cells treated with PF3758309 [CR]

Project description:3 BRAF/MEK inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)

2017-07-31 | GSE96902 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data